| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
William Jl Rieflin is Director at RAPT. William Jl Rieflin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $292K at current prices.
Net of sales, the RAPT filings show accumulation of 18,000 shares.
William Jl Rieflin has 18 Form 4 filings on record from October 2019 to August 2026, across 3 companies: Director at Lycia Therapeutics (LYCA), 2026; Director at Lyell Immunopharma (LYEL), 2022–2026; Director at RAPT Therapeutics (RAPT), 2019–2024.
The 22 reported transactions were 18 option or other derivative awards, 2 open-market purchases and 2 conversions.
Counted by filing, the open-market trades come to 2 purchases worth about $258K and no sales.
The largest open-market purchase was 10,000 shares of RAPT at an average $16.22 on November 19, 2020, about $162K.